The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
No material reason for the decrease, similar can be seen elsewhere. Still slightly higher than this time last year around the time of the dilutive fundraise. With cash still in the bank, we're getting very close to a superb price to buy that I'd suggest doesn't give any value to exosomes.
Hi Leem1 you did well to get out when you did, I think I may have an idea why the price is still falling, Schroder sold 3.22mill shares in September 2021 , taking their share of the company down from 9.27% to 3.61% (I do not recall a RSM from the company on this though) ,It would take many weeks for the brokers to dispose of the stock given the low level of dealing. It is now December and hopefully they have found a home for the 3.11 million shares.
At the 10 Dec 2021, this is the state of the Major Share holders Obotritia 10.72%, Griffiths Richard 7.97%, Octopus 5.87% Rosetta 5.64% ,Arix capt5.26%, Schoder 3.61%, The Invus Group 3.04%, Evans Sir Christopher 2.95%, Evans Mark 1.56%, Spreadex 1.17%, The only purchases from the above from September 2021 are from Invus group why bought 1.73 mill shares and Aberdeen Asset who bought 0.59 mill shares. None of the Major share holders have sold except Schroder.
With over 3.22 million share being offloaded the there will always be a downward pressure on the SP.
As a LTSH I hope next year will bring a rise in the SP and no more large sales from the big players.
Wide market
Consistent with falls everywhere else - Renx / MXCT / Orph etc
Anyone have a clue what on earth is going on here? Glad I sold but this thing is in freefall, why?
Totally agree. Reneuron have cash and have also shown good financial management so I cannot see a placing any time soon. With the RP treatment I would expect a major pharma to come on board with funding to get the treatment to market if required (if I remember correctly the current treatment they have for RP passes relevant safety criteria to allow it for use if they decided to market it sooner rather than later).
I have no idea why the price is dropping when all news seems to be positive at present.Could just be a mix of other news (Omicron,Theranos scandal,speculators getting cold feet re. lack of news on deals etc). We should have updates within weeks on latest RP trials at which point the brokers will issue a revised target price.That will be interesting as more positive news has emerged since last update other than the RP treatment-I would expect target price to increase.
I have topped up a little again today as I feel the price is far too low,but this will be it now.Hopefully the faith of all the LTI's will be rewarded sooner rather than later. 2022 looks to be a pivotal year for Reneuron as their products are being positively reviewed by their peers,and hopefully a really positive one!
Grizzlyb...totally agree that this stock is grossly undervalued!
It's not just ReNeuron that's down, so I don't think it signifies anything specific to us. As Phil has said, we have a minimum of 12 months cash.
From the progress overview shown in the interim results the most advanced exosome programme is an academic collaboration at present, so it'd be interesting to know how the next steps will be funded - I can't imagine it'll be very lucrative unless a commercial partner comes onboard.
That said, if we excluded exosomes and only had hRPC and CTX, I struggle to believe the value would be much different to our current value, so I still consider us to be grossly undervalued.
You can't rule anything out, but I personally doubt a raise is coming. They said there is a 12 month cash runway (minimum) from the start of this month. If they don't sign an exosome licencing deal in Q1 2022, then I'll be genuinely amazed. This will come with significant upfront payments that would potentially negate the requirement for any fundraise for a number of years.
I agree , this was the pattern before the last placing.
Do you think the SP is falling because a placing is coming soon?
Nickolas Peter I to have eternal hope but even after Zacks increased the rating on Reneuron from hold to buy on the 7th Dec the price is still going down, And I am not sure how much more it will go. I think Leem1 had lost patience and got out but as a long term holder I will give a few more months.
Had enough, I’m out- good luck guys no more patience
Looks like we've both search and found the same publication Phil. They're excited about overcoming the blood-brain barrier with a toxic dose, imagine the excitement if ReNeuron are able to cross it with a safe, controlled and therapeutically active dose of loaded exosomes.
Lots to digest from the interim results presentation, and I think that the company are clearly very excited about the developments that are taking place in the ongoing studies.
The information presented in the slides was quite illuminating. Of particular note (for me) was the slide that showed the progress with external partners. The one with the 'global pharma' partner indicates that the payload is an HDO, or heteroduplex oligonucleotide.
Below is an article from The Scientist publication regarding a breakthrough in the delivery of HDO from August 2021.
What I find particularly interesting is the comments from a couple of scientists who reviewed the study findings...
"The data seem strong,” Rudy Juliano, an emeritus professor at the University of North Carolina School of Medicine who did not participate in the study, writes in an email to The Scientist. Open questions, he adds, include whether most of the effect observed in the whole brain actually took place in neurons and not in supporting tissues, if the high doses the authors used—50 milligrams of HDO per kilogram of body weight—can be toxic, and why “this simple modification of oligo structure can overcome the extremely robust blood-brain barrier that limits the access of much smaller and much less polar molecules to the brain.”
“The first thing that struck me was the enormous dose that they are using. Fifty milligrams per kilogram is very high,” agrees David Male, a cell biologist at The Open University in the UK who was not involved in the work. It’s important to consider the dosing for clinical applications, he adds. “You might want to knock down inflammation in the brain in say, multiple sclerosis. You’re probably going to have to be giving quite sizable doses on quite a long-term basis if you’re just giving an oligonucleotide, which doesn’t effectively regenerate itself.”
https://www.the-scientist.com/news-opinion/antisense-oligonucleotides-cross-rodents-blood-brain-barrier-69104
The question therefore is whether the Rene CTX derived exosomes can replicate the loading and delivery efficacy across the "extremely robust blood-brain-barrier" observed for the therapeutic proteins announced by Rene in October. If so, then we may too be reading about further breakthroughs in The Scientist before long.
Pretty sure they got in a Tory public relations person to write that slogan. Hopefully more accurate and meaningful than the catchphrases Boris an Co. usually come out with!
Right Place, Right Time, Right Technology.
How could we not have confidence!
The time it has taken to treat only 9 patients in comparison in the Ph2a ext vs the larger sample in jCyte's completed Phase2b has, perhaps, brought home the commercial realities of using the two different techniques.
The commentary about "tough decisions" sounds similar to that used to justify abandoning the internal development of CTX stroke.
Interesting few posts, particularly Mol's grounding in a form of reality. Fosun seems to demonstrate early licensing deals, certainly pre-product, are not necessarily a panacea for share holders other than to off load R&D costs. So whether the next one relates to the more advanced efficacy trials or exosomes time will only tell, as will the value added such a deal may bring! As Stateside implies however I found the Chair's statement illuminating. Perhaps for the first time I heard a senior board member talk about commercials and share holder value. Whether this signals the opening of a fissure between an ambitious chair and a laissez faire Executive time will again tell! As Mol seems to suggest the present CEO has administered rather than lead this business, living off the same old utterances. Crumbs of course that keep many going.
Whilst my general theme on this board is one of frustration, having lost over the years too many dollars to count, nonetheless I too will hang around. Have a good December.
Mol42.
Yes. Maybe you have some relevant points there but - and it's a big but - the board has been beefed up recently and got some real talent and experience on board now. We have to wait awhile to see what difference they will make.
I remain hopeful.
bit more re CLI and Peripheral nerve damage
https://www.manufacturingchemist.com/news/article_page/ReNeuron_to_use_Cellmate_automated_cell_culture_for_stem_cell-based_stroke_therapy/108086
https://www.ucl.ac.uk/news/2018/feb/shelf-living-artificial-tissues-could-repair-severe-nerve-injuries
https://www.labnews.co.uk/article/2025121/investment_for_nerve_engineering_spinout
just a bit of info - albeit from the past
BW all
mol
The elephant has unfortunately, over the years ,has never been out of the room in my opinion but just reappears as REN....
or perhaps they use another designation now - haven't checked
This company has never been able to commercialise a product to date - which to me is a really sad indication of the science behind their research - and the UK in general
I think the company continues to be at the forefront (albeit don't follow to the same extent)
and now Olav's gold dust has become the driver - a bit of news before his appointment undernoted
https://www.reneuron.com/news-list/reneuron-presents-new-pre-clinical-data-demonstrating-therapeutic-effects-of-nanoparticles-released-from-its-stem-cells/
and I could go on with the past but won't
something for the future - release date 2022
https://discovery.ucl.ac.uk/id/eprint/10129235/
Sad reflection that this company hasn't achieved what I really thought it was capable of a number of years ago
and a prominent investor also, who I believe has recently stepped down from the board but remains a shareholder, perhaps shares the frustration.
mol
Elephant in the room is this:
'The data from the extension study and the earlier lower dose cohort will inform the Company as to the preferred dosing based on its efficacy and safety profile, whether sub-retinal delivery provides the optimal efficacy and duration of action and the commercial potential. The data will support the decision whether to move straight into a pivotal trial or whether additional subjects should be treated to garner further sub-retinal data and also whether to investigate further a move into the clinic with an intravitreal dosing regimen.'
Think they must not be getting the improvement in efficacy data they were hoping for from the increased dosage, based on the initial patients treated in the expanded phase 2a study. The data can still be good, but perhaps not to the extent that it outweighs the increased risk of having two subretinal bleb sites.
However, as they have previously stated, they think based on 1 million cell dosage they have an approvable efficacy signal, so not exactly a bad position to be in when designing a pivotal study.
What I think is telling is the Chairman's statement, as follows:
'Despite the breadth of our stem cell based platforms, if we are to succeed, we need to be prepared to make tough decisions and only progress and invest in those programmes whereby true value can be created. Accordingly, where necessary we will look to share the value creating potential of our assets to secure substantive third-party collaborations, thereby increasing significantly the probability of success in terms of product development and value creation. The Board and management team will continue to assess all opportunities to create value through organic growth but also, as appropriate, explore technology licensing and acquisition opportunities to accelerate and enhance the overall value proposition of our Company.'
For me, reading between the lines, I think 'tough decisions' refers to out-licencing hRPC programme once the data is in at Q1 2022. A pivotal study would be expensive, and I think they would now be happy to take a licencing deal with upfront payment and royalties, and let someone else take on the risk and expense of the pivotal study.
The strategy to me now seems clear; put everything behind the exosomes programme in the near term, because the opportunity they have is potentially huge. Talk of potential 'acquisition opportunities' perhaps relates to how they can expand/scale exosome manufacturing, and presumably whether that can be funded by selling the rights to hRPC.
That's my take anyway. See if they put any more detail forward during the presentation later.
It's a reasonably positive update. But the company has been operational now for over 15 years with negligible revenues. So the fact everything is continually so forward looking still is why the share price continues to be depressed. Reflects a lack of tangible commercial progress over an extended timeframe. But I personally remain invested and with eternal hope!
Interim results are never very interesting other than cash burn.................be interested to listen to the Investor Meet this afternoon as that will likely be more revealing about what is going on behind the scenes and forthcoming developments which will drive the SP
Olav...
"We feel we are in the right place, at the right time, with the right technology to be a leader in exosomes and look forward to providing further updates on our progress as the excitement in this area continues to grow.”
Sounds good to me.